Thu, Apr 17, 2014, 12:10 AM EDT - U.S. Markets open in 9 hrs 20 mins


% | $
Quotes you view appear here for quick access.

Amgen, Inc. (AMGN) Message Board

  • jeremysikessr jeremysikessr May 1, 2013 10:42 AM Flag

    NEW AMGN TARGET raised 30% to $130!!!! At GOLDMAN!!!! CONVICTION BUY!!!

    NEW AMGN TARGET raised 30% to $130!!!! At GOLDMAN!!!! CONVICTION BUY!!!

    Amgen upgraded to Conviction Buy from Neutral

    Goldman Sachs has upgraded the company to its Conviction Buy list, with a price target of $130 up from $100, citing a “more favorable combination of catalysts and upside potential.” ”We project that AMGN’s pipeline (key readouts in 1Q14-2015) and own biosimilars (first launch in 2017) will allow it to replace the potential revenue that could be lost to competition and grow its base,” Goldman analyst Terence Flynn said.
    Goldman upgraded Amgen (AMGN) based on valuation and its late-stage pipeline which is highly innovative and has the potential to replace key biologic franchises that are coming off patent.

    Could easily be 107 or better this week


    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • AMGN is a biotechnology medicines company that engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada
      Recently, Amgen (AMGN) reported very interesting topline results from a melanoma drug, which is also very exciting. We don't know the details, but at least the top line sounds encouraging

      Sentiment: Strong Buy

115.54+0.54(+0.47%)Apr 16 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.